Abata Therapeutics
Valerie Odegard, Ph.D., is a successful biotechnology executive with more than 15 years of experience in the development of immunotherapies to treat autoimmune/inflammatory disease, cancer and infectious disease. Valerie is currently the President and Chief Scientific Officer of Silverback Therapeutics ($SBTX), a clinical-stage biotechnology company developing tissue-targeted therapeutics. Previously, she was Vice President of R&D at Juno Therapeutics, where she was responsible for the development of novel cellular immunotherapies prior to Juno’s acquisition by Celgene. Valerie held leadership positions at Novo Nordisk and Trubion Pharmaceuticals, where she oversaw the development of therapeutics for oncology and inflammatory conditions. She received her Ph.D. in Immunobiology from Yale University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Abata Therapeutics
1 followers
Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.